Grand Pharmaceutical Group Limited (Grand Pharma) released its 2025 Environmental, Social and Governance Report, outlining solid operating growth, expanded R&D investment and upgraded sustainability commitments.
Financial and Dividend Highlights • Revenue reached HK$12.28 billion, up 5.5% year-on-year. • Cash dividend proposed at roughly HK$600 million, translating into a 47.7% payout ratio; cumulative dividends since listing stand at about HK$4.30 billion.
R&D and Innovation • Total R&D expenditure amounted to HK$1.46 billion. • Project pipeline comprised 131 ongoing programmes, including 39 innovative projects; 65 milestone developments and 32 innovative project advances were recorded. • Five innovative and 20 generic products, plus six new API registrations, received marketing authorisations during the year. • Innovative products contributed more than 50% of total revenue for the first time.
Product Accessibility & Affordability • Over 260 products are now listed in China’s National Reimbursement Drug List; more than 130 products feature in the National Essential Drug List. • Patient-focused initiatives such as the “Yttrium Little Red Flower” programme expanded, bringing cumulative assistance to over 1,500 patients.
Governance and Business Ethics • Board-led ESG framework supported by a Strategy & ESG Committee and dedicated working group. • More than 30 business-ethics audits conducted, covering 100% of operating sites; no material corruption or data-security cases recorded. • 100% employee participation and pass rate in code-of-conduct and anti-corruption training.
Workforce Development & Safety • Total headcount: 12,614 full-time employees; 3,773 new hires in 2025, including 715 campus recruits. • Average training hours per employee reached 25.80; 100% training coverage achieved. • Zero major employee safety accidents; 33 subsidiaries completed safety-risk identification and ISO 45001 certification coverage rose to 18 sites.
Climate & Environmental Performance • ISO 14001 certification now covers 58% of production sites; four subsidiaries are ISO 50001 energy-management certified. • GHG emissions (Scope 1 & 2) totalled 400,551 tCO₂e, with intensity at 32.62 tCO₂e per HK$ million revenue. • Targets include a 10% reduction in GHG-emission intensity and 6% cuts in both energy and water intensity by 2030 (base year 2023). • Twenty-two energy-saving projects launched, projecting annual cost savings of RMB34.73 million; subsidiaries procured 6,415 MWh of green electricity.
Supply Chain & Community • Supplier base stood at 1,413, with 550 quality audits completed; 100% compliance with business-ethics clauses. • Community donations totalled approximately RMB63.30 million, a 195% increase year-on-year, supporting healthcare access, education and disaster relief.
Strategic Outlook Grand Pharma will continue to pursue its “independent R&D + global expansion” strategy, prioritising nuclear medicine, critical care and biotechnology, while executing its carbon-reduction roadmap and strengthening supply-chain resilience.
Comments